This is a working overview of c-Met receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-11 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
=== Stigma === Heroin users are often referred to as 'amaparas' a term that researchers say is a dehumanizing and derogatory term that implies worthlessness and criminality. The term is perpetuating marginalization and discrimination, while preventing an understanding of the addiction crisis as a medical issue and addicts as people requiring social support.
=== Europe === Lancaster AMS-UK for trace actinides and radiocarbon at Lancaster University, England Vilnius Radiocarbon AMS dating laboratory in Vilnius, Lithuania Centre for Isotope Research on Cultural and Environmental heritage (CIRCE) [1], Mathematics and Physics Department [2], Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy CEREGE in Aix en Provence, France LMC14 Laboratoire de mesure du carbone 14, at LSCE, Saclay, France LSCE-ECHoMICADAS, at LSCE, Gif-sur-Yvette, France 14Chrono Centre for Climate, the Environment, and Chronology Queen's University Belfast, Northern Ireland Bristol Radiocarbon Accelerator Mass Spectrometer at University of Bristol, England RICH, Royal Institute for Cultural heritage, Brussels, Belgium CologneAMS at University of Cologne, Germany Hertelendi Laboratory of Environmental Studies at ATOMKI, Debrecen, Hungary DREAMS at Dresden, Germany Centre for Isotope Research Rijksuniversiteit Groningen, The Netherlands Beta Analytic Europe in London, England Tandem Laboratory at Uppsala University in Uppsala, Sweden Lund Accelerator Mass Spectrometry Facility at Lund University, Sweden RoAMS Laboratory of the "Horia Hulubei" National Institute for Physics and Nuclear Engineering Măgurele, Romania AMS at the Maier-Leibnitz-Laboratory joint facility of LMU Munich and Technical University of Munich, Germany Oxford Radiocarbon Accelerator Unit, University of Oxford, United Kingdom Poznan Radiocarbon Laboratory, Poland Centre for Dating and Diagnostics (CEDAD), University of Salento, Italy [3] Centro Nacional de Aceleradores, CNA University of Sevilla, Spain NERC Recognised Accelerator Mass Spectrometer at SUERC, Scotland Vienna Environmental Research Accelerator at the University of Vienna, Austria Ion Beam Physics Laboratory of the ETH Zurich and the Paul Scherrer Institute, Switzerland National 1MV AMS Laboratory, TÜBİTAK Marmara Research Center Turkey Nuclear Physics Institute, The Czech Academy of Sciences, Czech Republic
After Reagan's military buildup, the Soviet Union did not respond by further building its military, because the enormous military expenses, along with inefficient planned manufacturing and collectivized agriculture, were already a heavy burden for the Soviet economy. At the same time, Saudi Arabia increased oil production, even as other non-OPEC nations were increasing production. These developments contributed to the 1980s oil glut, which affected the Soviet Union as oil was the main source of Soviet export revenues. Issues with command economics, oil price decreases and large military expenditures gradually brought the Soviet economy to stagnation.
Sources: en.wikipedia.org
In 1210, all Jewish householders in England were imprisoned in Bristol and a hefty levy of 60,000 or 66,000 marks was imposed on them. During the Second Barons' War, the city's archa was burned and the Jewish community was violently attacked. There was another attack in 1275, but without fatalities. The community was expelled with the rest of England's Jews in 1290. There is a surviving Jewish ritual bath, from this time period now known as Jacob's Well. First interpreted as a mikveh, this was subsequently re-evaluated as a Bet Tohorah, associated with the nearby Jewish cemetery at Jews Acre.
==== Metformin ==== One of the most common drugs used in T2D, metformin is the drug of choice to help patients lower their blood sugar levels. Metformin is an example of a class of medicine called biguanides. The medication works by reducing the new creation of glucose from the liver and by reducing absorption of sugar from food. In addition, the medication also works to help increase the effects of insulin on muscle cells, which take in glucose. The medicine is not used for T1D as these patients do not produce any insulin and metformin relies on some insulin production in order to be effective. There are several preparations of the medication such as tablets, extend release tablets, and liquid suspensions. Metformin is usually started as 500 to 1000 mg tablets twice a day by mouth (PO), usually with meals. If taking the extended release tablets, they should be always swallowed whole as cutting the tablet will cause faster release of the medication. The medication most commonly may cause side effects such as stomach upset and diarrhea, but in general is well tolerated and has a relatively low chance of causing hypoglycemia. One rare (about 1% chance) but serious side effect of metformin is that it can cause lactic acidosis, usually in patients with poor kidney function. To assist in tolerance of the metformin, practitioners may recommend gradual increase of the dose of the medication.
=== Wilson's disease ATPase === Sarkar's laboratory identified six copper-binding sites of Wilson's disease ATPase with all six copper atoms binding ATPase in +1-oxidation state. Based on nuclear magnetic resonance (NMR) studies, Sarkar's team proposed that copper transfer to and between the N-terminal domains of the Wilson ATPase occurs via protein interactions that are facilitated by the flexibility of the linkers and the motional freedom of the domains with respect to each other.
Sources: en.wikipedia.org
In 2014, a Milwaukee Starbucks employee called the police when they noticed a black man sleeping in a park, which resulted in the police officer killing the man by shooting him 14 times, prompting protests. In 2018, two black men were arrested and escorted out of a Philadelphia Starbucks after the staff called the police because they refused to leave. The video of the incident quickly became viral and sparked widespread outrage. In another 2018 incident, a black man was denied the code for the restroom for not being a customer, even though at the same time a white man was given that code before ordering anything. In 2021, a Starbucks in Ireland was fined €12,000 after an Irish Thai customer received her order with a racist drawing on the cup.
=== Neurological === CCK is found extensively throughout the central nervous system, with high concentrations found in the limbic system. CCK is synthesized as a 115 amino acid preprohormone, that is then converted into multiple isoforms. The predominant form of CCK in the central nervous system is the sulfated octapeptide, CCK-8S.
== Further reading == Gadd, Pia; Olofsson, Clark (1991). Att aldrig gå loss: mekanismerna som gör fängelserna självförsörjande : samtal med Clark Olofsson [To Never Break Free: The Mechanisms That Make Prisons Self-Sufficient: Conversations with Clark Olofsson] (in Swedish). Stockholm: Carlsson. ISBN 9177984854. SELIBR 7666067.
== Modeling == Models have been developed to simplify conceptualization of the many processes that take place in the interaction between an organism and a chemical substance. Pharmacokinetic modelling may be performed either by noncompartmental or compartmental methods. Multi-compartment models provide the best approximations to reality; however, the complexity involved in adding parameters with that modelling approach means that monocompartmental models and above all two compartmental models are the most-frequently used. The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine. Models generally take the form of mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism. A variety of analysis techniques may be used to develop models, such as nonlinear regression or curve stripping.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.